Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 24
341
Views
9
CrossRef citations to date
0
Altmetric
Short Communications

Bilobetin, a novel small molecule inhibitor targeting influenza virus polymerase acidic (PA) endonuclease was screened from plant extracts

&
Pages 5968-5971 | Received 21 Feb 2020, Accepted 02 Aug 2020, Published online: 21 Aug 2020
 

Abstract

The influenza A virus polymerase acidic (PA) endonuclease is an attractive target for anti-influenza drug development. In this study, plant extracts were used to screen the inhibitor against the PA endonuclease and its mutant. In 45 kinds of plant extracts, eight can effectively inhibit the PAN and PAN–I38T mutant in the primary screening. Dose-dependent inhibition assay showed that Epimedii folium can effectivity inhibit the PAN and PAN–I38T with IC50 of 11.23 and 26.03 μM, respectively. Furthermore, 130 ingredients of E. folium were virtually screened using the in silico method, and the compounds ginkgetin and bilobetin bind to the active pocket of PAN and PAN–I38T with a strong interaction force. Gel-based PA endonuclease analysis and inhibition type analysis identified that bilobetin can competitively inhibit the PA. Hence, bilobetin, as an ingredient of E. folium, was screened through in vitro and in silico research.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the National Natural Science Foundation of China [grant no. 81603459].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.